Latest news

• Pfizer files third-gen ALK inhibitor for lung cancer

  Pfizer files third-gen ALK inhibitor for lung cancer. The US FDA is set to make a decision on lorlatinib later this year. ... Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori

• Roche gets FDA OKs for Alecensa and Zelboraf

  Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as

• Novartis gets first-line approval for Xalkori challenger in EU

  Novartis' Zykadia can now compete head-to-head in Europe against Pfizer's Xalkori after winning approval as a first-line therapy for ALK-positive non-small cell lung cancer (NSCLC). ... It is only the second ALK inhibitor approved for first-line use in

• Novartis' Zykadia claims US approval for first-line lung cancer

  The approval is good news for Novartis, although its key competitor in the coming period will not be so much Xalkori as Roche's ALK inhibitor Alecensa (alectinib), which bested ... Meanwhile additional competition in the ALK inhibitor market is looming

• Novartis' Zykadia prepped to take on Xalkori in Europe

  More patients in Europe should be eligible for treatment with Novartis' Zykadia after the EMA's advisory committee backed first-line use of the ALK inhibitor. ... Previously Zykadia was only approved for use in ALK-positive NSCLC patients whose disease